Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Charles River Laboratories (CRL) shares plunge after Justice Department subpoena relating to NHPs
February 22, 2023 12:16 PM ESTCharles River Laboratories (NYSE: CRL) shares plummeted over 14% Wednesday after the company said in its latest earnings report that it has received a subpoena from the U.S. Department of Justice in connection with an investigation into the Cambodian non-human primate (NHP) supply... More
Charles River Laboratories (CRL) Tops Q4 EPS by 23c; Guides FY23 EPS Below Views
February 22, 2023 7:06 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.98, $0.23 better than the analyst estimate of $2.75. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $9.70-$10.90. Charles River... More
